NCT02280811 · STUDY IN CONTEXT

T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

The MTD is the highest dose at which ≤1 of 6 patients experienced a dose limiting toxicity (DLT) or the highest dose level studied if DLTs are not observed at any of the dose levels.

Source null

→

primary · POSTED

Objective tumor response rate is defined as the number of participants with a complete or partial response per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.0. Complete response is disappearance of all target lesions. Partial response is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.

Source null

→

primary · POSTED

Duration of response is measured from the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Response is assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.0. Complete response is disappearance of all target lesions. Partial response is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Progression is at least a 20% increase in the sum of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

Source null

→

secondary · POSTED

Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

Source null

→

secondary · POSTED

A dose limiting toxicity is all Grade 3 and greater toxicities with the exception of myelosuppression, defined as lymphopenia, neutropenia, decreased hemoglobin, and thrombocytopenia, due to chemotherapy preparative regimen. Aldesleukin expected toxicities as defined in Appendix 2 and 3 of the protocol. Expected chemotherapy toxicities as defined in the pharmaceutical information section. Immediate hypersensitivity reactions (excluding symptomatic bronchospasm and grade 4 hypotension) occurring within 2 hours of cell infusion (related to cell infusion) that are reversible to a grade 2 or less within 24 hours of cell administration with standard therapy. Grade 3 fever. Events that are clearly related to the patient's disease.

Source null

→

secondary · POSTED

Detection of E6 TCR T cells in patients peripheral blood leukocytes (PBL)/apheresis samples by flow cytometry.

One patient in group HPV-16 E6 mTCR PBL 1x10\^10 + HD IL-2 did not have research blood collected at one month post infusion, and thus could not examine the cells for that patient at that time point.

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-anal-cancer
nct id: NCT02280811
trial label: T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
applicability: narrower
applicability note: Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 6
harms Count: 6
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT02280811
outcome key
om-0000
source section id
NCT02280811-om-0000
source outcome index
0
endpoint
Maximum Tolerated Dose (MTD)
endpoint definition
The MTD is the highest dose at which ≤1 of 6 patients experienced a dose limiting toxicity (DLT) or the highest dose level studied if DLTs are not observed at any of the dose levels.
time origin
participants were followed for the duration of hospital stay, an average of 3 weeks
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT02280811
outcome key
om-0001
source section id
NCT02280811-om-0001
source outcome index
1
endpoint
Objective Tumor Response Rate (Complete or Partial Response)
endpoint definition
Objective tumor response rate is defined as the number of participants with a complete or partial response per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.0. Complete response is disappearance of all target lesions. Partial response is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.
time origin
4 years
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT02280811
outcome key
om-0002
source section id
NCT02280811-om-0002
source outcome index
2
endpoint
Duration of Response
endpoint definition
Duration of response is measured from the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Response is assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.0. Complete response is disappearance of all target lesions. Partial response is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Progression is at least a 20% increase in the sum of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
time origin
up to one year
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT02280811
outcome key
om-0003
source section id
NCT02280811-om-0003
source outcome index
3
endpoint
Number of Participants With Serious and Non-serious Adverse Events
endpoint definition
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
time origin
19 months and 7 days
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT02280811
outcome key
om-0004
source section id
NCT02280811-om-0004
source outcome index
4
endpoint
Number of Participants With a Dose Limiting Toxicity (DLT)
endpoint definition
A dose limiting toxicity is all Grade 3 and greater toxicities with the exception of myelosuppression, defined as lymphopenia, neutropenia, decreased hemoglobin, and thrombocytopenia, due to chemotherapy preparative regimen. Aldesleukin expected toxicities as defined in Appendix 2 and 3 of the protocol. Expected chemotherapy toxicities as defined in the pharmaceutical information section. Immediate hypersensitivity reactions (excluding symptomatic bronchospasm and grade 4 hypotension) occurring within 2 hours of cell infusion (related to cell infusion) that are reversible to a grade 2 or less within 24 hours of cell administration with standard therapy. Grade 3 fever. Events that are clearly related to the patient's disease.
time origin
19 months and 7 days
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT02280811
outcome key
om-0005
source section id
NCT02280811-om-0005
source outcome index
5
endpoint
Percentage of Cluster of Differentiation 3 (CD3+) Cells That Are E6 T-Cell Receptor Memory of Circulating T-Cells in Responders and Non-responders
endpoint definition
Detection of E6 TCR T cells in patients peripheral blood leukocytes (PBL)/apheresis samples by flow cytometry.
time origin
One month after treatment
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
One patient in group HPV-16 E6 mTCR PBL 1x10\^10 + HD IL-2 did not have research blood collected at one month post infusion, and thus could not examine the cells for that patient at that time point.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT02280811
outcome key
om-0000
arm key
OG000
arm label
All Treated Subjects
regimen
All treated subjects who received at least one dose of human papilloma virus (HPV)-16 E6 monoclonal T cell receptor (mTCR) peripheral blood lymphocytes (PBL) 1x10\^9, 1x10\^10,1x10\^11, \>1x10\^11 up to 2x10\^11 + high-dose (HD) interleukin 2 (IL-2) were included.
analyzed count
10
analyzed unit
Participants
is comparator
Source null
source pointer
NCT02280811-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT02280811
outcome key
om-0001
arm key
OG000
arm label
HPV-16 E6 mTCR PBL 1x10^9 + HD IL-2
regimen
patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin Fludarabine: Patients will receive Fludarabine 25 mg/m\^2/day for 5 days. Cyclophosphamide: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days E6 TCR: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine) Aldesleukin: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
analyzed count
1
analyzed unit
Participants
is comparator
Source null
source pointer
NCT02280811-om-0001#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT02280811
outcome key
om-0001
arm key
OG001
arm label
HPV-16 E6 mTCR PBL 1x10^10 + HD IL-2
regimen
patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin Fludarabine: Patients will receive Fludarabine 25 mg/m\^2/day for 5 days. Cyclophosphamide: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days E6 TCR: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine) Aldesleukin: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
analyzed count
2
analyzed unit
Participants
is comparator
Source null
source pointer
NCT02280811-om-0001#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT02280811
outcome key
om-0001
arm key
OG002
arm label
HPV-16 E6 mTCR PBL 1x10^11 + HD IL-2
regimen
patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin Fludarabine: Patients will receive Fludarabine 25 mg/m\^2/day for 5 days. Cyclophosphamide: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days E6 TCR: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine) Aldesleukin: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
analyzed count
1
analyzed unit
Participants
is comparator
Source null
source pointer
NCT02280811-om-0001#groups/OG002
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT02280811
outcome key
om-0001
arm key
OG003
arm label
HPV-16 E6 mTCR PBL >1x10^11 up to 2x10^11 + HD IL-2
regimen
patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin Fludarabine: Patients will receive Fludarabine 25 mg/m\^2/day for 5 days. Cyclophosphamide: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days E6 TCR: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine) Aldesleukin: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
analyzed count
6
analyzed unit
Participants
is comparator
Source null
source pointer
NCT02280811-om-0001#groups/OG003
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT02280811
outcome key
om-0001
arm key
OG004
arm label
HPV-16 E6 mTCR PBL MTD + HD IL-2
regimen
patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin Fludarabine: Patients will receive Fludarabine 25 mg/m\^2/day for 5 days. Cyclophosphamide: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days E6 TCR: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine) Aldesleukin: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
analyzed count
2
analyzed unit
Participants
is comparator
Source null
source pointer
NCT02280811-om-0001#groups/OG004
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT02280811
outcome key
om-0002
arm key
OG000
arm label
HPV-16 E6 mTCR PBL 1x10^9 + HD IL-2
regimen
patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin Fludarabine: Patients will receive Fludarabine 25 mg/m\^2/day for 5 days. Cyclophosphamide: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days E6 TCR: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine) Aldesleukin: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
analyzed count
1
analyzed unit
Participants
is comparator
Source null
source pointer
NCT02280811-om-0002#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT02280811
outcome key
om-0002
arm key
OG001
arm label
HPV-16 E6 mTCR PBL 1x10^10 + HD IL-2
regimen
patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin Fludarabine: Patients will receive Fludarabine 25 mg/m\^2/day for 5 days. Cyclophosphamide: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days E6 TCR: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine) Aldesleukin: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
analyzed count
2
analyzed unit
Participants
is comparator
Source null
source pointer
NCT02280811-om-0002#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT02280811
outcome key
om-0002
arm key
OG002
arm label
HPV-16 E6 mTCR PBL 1x10^11 + HD IL-2
regimen
patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin Fludarabine: Patients will receive Fludarabine 25 mg/m\^2/day for 5 days. Cyclophosphamide: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days E6 TCR: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine) Aldesleukin: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
analyzed count
1
analyzed unit
Participants
is comparator
Source null
source pointer
NCT02280811-om-0002#groups/OG002
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT02280811
outcome key
om-0002
arm key
OG003
arm label
HPV-16 E6 mTCR PBL >1x10^11 up to 2x10^11 + HD IL-2
regimen
patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin Fludarabine: Patients will receive Fludarabine 25 mg/m\^2/day for 5 days. Cyclophosphamide: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days E6 TCR: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine) Aldesleukin: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
analyzed count
6
analyzed unit
Participants
is comparator
Source null
source pointer
NCT02280811-om-0002#groups/OG003
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT02280811
outcome key
om-0002
arm key
OG004
arm label
HPV-16 E6 mTCR PBL MTD + HD IL-2
regimen
patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin Fludarabine: Patients will receive Fludarabine 25 mg/m\^2/day for 5 days. Cyclophosphamide: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days E6 TCR: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine) Aldesleukin: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
analyzed count
2
analyzed unit
Participants
is comparator
Source null
source pointer
NCT02280811-om-0002#groups/OG004
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT02280811
outcome key
om-0003
arm key
OG000
arm label
HPV-16 E6 mTCR PBL 1x10^9 + HD IL-2
regimen
patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin Fludarabine: Patients will receive Fludarabine 25 mg/m\^2/day for 5 days. Cyclophosphamide: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days E6 TCR: On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine) Aldesleukin: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
analyzed count
1
analyzed unit
Participants
is comparator
Source null
source pointer
NCT02280811-om-0003#groups/OG000

harms

release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT02280811
harm key
EG000
source section id
NCT02280811-ae
event group key
EG000
event group label
HPV-16 E6 mTCR PBL 1x10^9 + HD IL-2
serious affected
0
serious at risk
1
other affected
1
other at risk
1
frequency threshold
0
collection period
19 months and 7 days
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT02280811
harm key
EG001
source section id
NCT02280811-ae
event group key
EG001
event group label
HPV-16 E6 mTCR PBL 1x10^10 + HD IL-2
serious affected
1
serious at risk
2
other affected
2
other at risk
2
frequency threshold
0
collection period
19 months and 7 days
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT02280811
harm key
EG002
source section id
NCT02280811-ae
event group key
EG002
event group label
HPV-16 E6 mTCR PBL 1x10^11 + HD IL-2
serious affected
0
serious at risk
1
other affected
1
other at risk
1
frequency threshold
0
collection period
19 months and 7 days
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT02280811
harm key
EG003
source section id
NCT02280811-ae
event group key
EG003
event group label
HPV-16 E6 mTCR PBL >1x10^11 up to 2x10^11 + HD IL-2
serious affected
2
serious at risk
6
other affected
6
other at risk
6
frequency threshold
0
collection period
19 months and 7 days
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT02280811
harm key
EG004
source section id
NCT02280811-ae
event group key
EG004
event group label
HPV-16 E6 mTCR PBL MTD + HD IL-2
serious affected
2
serious at risk
2
other affected
2
other at risk
2
frequency threshold
0
collection period
19 months and 7 days
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-anal-cancer
nct id
NCT02280811
harm key
EG005
source section id
NCT02280811-ae
event group key
EG005
event group label
HPV-16 E6 mTCR PBL MTD + HD IL-2-Retreatment
serious affected
0
serious at risk
1
other affected
1
other at risk
1
frequency threshold
0
collection period
19 months and 7 days
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice